Serum AGE/RAGEs As Potential Biomarker in Idiopathic Pulmonary Fibrosis

Overview

Journal Respir Res

Specialty Pulmonary Medicine

Date 2018 Nov 10

PMID 30409203

Citations 24

Authors

Carlos Machahua

Ana Montes-Worboys

Lurdes Planas-Cerezales

Raquel Buendia-Flores

Maria Molina-Molina

Vanesa Vicens-Zygmunt

Affiliations

Soon will be listed here.

Abstract

Background: The soluble receptor for advanced glycation end-products (sRAGE) has been suggested that it acts as a decoy for capturing advanced glycation end-products (AGEs) and inhibits the activation of the oxidative stress and apoptotic pathways. Lung AGEs/sRAGE is increased in idiopathic pulmonary fibrosis (IPF). The objective of the study was to evaluate the AGEs and sRAGE levels in serum as a potential biomarker in IPF.

Methods: Serum samples were collected from adult patients: 62 IPF, 22 chronic hypersensitivity pneumonitis (cHP), 20 fibrotic non-specific interstitial pneumonia (fNSIP); and 12 healthy controls. In addition, 23 IPF patients were re-evaluated after 3-year follow-up period. Epidemiological and clinical features were recorded: age, sex, smoking habits, and lung function. AGEs and sRAGE were evaluated by ELISA, and the results were correlated with pulmonary functional test values.

Results: IPF and cHP groups presented a significant increase of AGE/sRAGE serum concentration compared with fNSIP patients. Moreover, an inverse correlation between AGEs and sRAGE levels were found in IPF, and serum sRAGE at diagnosis correlated with FVC and DLCO values. Additionally, changes in serum AGEs and sRAGE correlated with % change of FVC, DLCO and TLC during the follow-up. sRAGE levels below 428.25 pg/ml evolved poor survival rates.

Conclusions: These findings demonstrate that the increase of AGE/sRAGE ratio is higher in IPF, although the levels were close to cHP. AGE/sRAGE increase correlates with respiratory functional progression. Furthermore, the concentration of sRAGE in blood stream at diagnosis and follow-up could be considered as a potential prognostic biomarker.

Citing Articles

Elucidating the causal associations and mechanisms between circulating immune cells and idiopathic pulmonary fibrosis: new insights from Mendelian randomization and transcriptomics.

Yang H, Wu X, Xiao X, Chen J, Yu X, Zhao W Front Immunol. 2025; 15:1437984.

PMID: 39896814 PMC: 11782250. DOI: 10.3389/fimmu.2024.1437984.

Serum soluble isoform of receptor for advanced glycation end product is a predictive biomarker for acute exacerbation of idiopathic pulmonary fibrosis: a German and Japanese cohort study.

Kitadai E, Yamaguchi K, Ohshimo S, Iwamoto H, Sakamoto S, Horimasu Y Respir Res. 2024; 25(1):405.

PMID: 39529063 PMC: 11552171. DOI: 10.1186/s12931-024-03014-7.

The functions and regulatory pathways of S100A8/A9 and its receptors in cancers.

Zhou H, Zhao C, Shao R, Xu Y, Zhao W Front Pharmacol. 2023; 14:1187741.

PMID: 37701037 PMC: 10493297. DOI: 10.3389/fphar.2023.1187741.

[The First Steps Towards the Future of ILD: Contributing to Knowledge].

Cano-Jimenez E, Ros Lucas J, Boldova Loscertales A, Ortega P Open Respir Arch. 2023; 4(3):100168.

PMID: 37496590 PMC: 10369576. DOI: 10.1016/j.opresp.2022.100168.

The soluble receptor for advanced glycation end products is potentially predictive of pulmonary arterial hypertension in systemic sclerosis.

Atzeni I, Al-Adwi Y, Doornbos-van der Meer B, Roozendaal C, Stel A, Goor H Front Immunol. 2023; 14:1189257.

PMID: 37409127 PMC: 10318928. DOI: 10.3389/fimmu.2023.1189257.

References

Inghilleri S, Morbini P, Campo I, Zorzetto M, Oggionni T, Pozzi E . Factors influencing oxidative imbalance in pulmonary fibrosis: an immunohistochemical study. Pulm Med. 2011; 2011:421409. PMC: 3109417. DOI: 10.1155/2011/421409. View

Oczypok E, Perkins T, Oury T . All the "RAGE" in lung disease: The receptor for advanced glycation endproducts (RAGE) is a major mediator of pulmonary inflammatory responses. Paediatr Respir Rev. 2017; 23:40-49. PMC: 5509466. DOI: 10.1016/j.prrv.2017.03.012. View

Hudson B, Carter A, Harja E, Kalea A, Arriero M, Yang H . Identification, classification, and expression of RAGE gene splice variants. FASEB J. 2007; 22(5):1572-80. DOI: 10.1096/fj.07-9909com. View

Ley B, Brown K, Collard H . Molecular biomarkers in idiopathic pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol. 2014; 307(9):L681-91. PMC: 4280147. DOI: 10.1152/ajplung.00014.2014. View

Lynch 3rd J, Huynh R, Fishbein M, Saggar R, Belperio J, Weigt S . Idiopathic Pulmonary Fibrosis: Epidemiology, Clinical Features, Prognosis, and Management. Semin Respir Crit Care Med. 2016; 37(3):331-57. DOI: 10.1055/s-0036-1582011. View

Rosas I, Richards T, Konishi K, Zhang Y, Gibson K, Lokshin A . MMP1 and MMP7 as potential peripheral blood biomarkers in idiopathic pulmonary fibrosis. PLoS Med. 2008; 5(4):e93. PMC: 2346504. DOI: 10.1371/journal.pmed.0050093. View

Avery N, Bailey A . The effects of the Maillard reaction on the physical properties and cell interactions of collagen. Pathol Biol (Paris). 2006; 54(7):387-95. DOI: 10.1016/j.patbio.2006.07.005. View

Manichaikul A, Sun L, Borczuk A, Onengut-Gumuscu S, Farber E, Mathai S . Plasma Soluble Receptor for Advanced Glycation End Products in Idiopathic Pulmonary Fibrosis. Ann Am Thorac Soc. 2017; 14(5):628-635. PMC: 5427736. DOI: 10.1513/AnnalsATS.201606-485OC. View

Drakopanagiotakis F, Wujak L, Wygrecka M, Markart P . Biomarkers in idiopathic pulmonary fibrosis. Matrix Biol. 2018; 68-69:404-421. DOI: 10.1016/j.matbio.2018.01.023. View

10.

Byun K, Yoo Y, Son M, Lee J, Jeong G, Park Y . Advanced glycation end-products produced systemically and by macrophages: A common contributor to inflammation and degenerative diseases. Pharmacol Ther. 2017; 177:44-55. DOI: 10.1016/j.pharmthera.2017.02.030. View

11.

Grunes D, Beasley M . Hypersensitivity pneumonitis: a review and update of histologic findings. J Clin Pathol. 2013; 66(10):888-95. DOI: 10.1136/jclinpath-2012-201337. View

12.

Hamai K, Iwamoto H, Ishikawa N, Horimasu Y, Masuda T, Miyamoto S . Comparative Study of Circulating MMP-7, CCL18, KL-6, SP-A, and SP-D as Disease Markers of Idiopathic Pulmonary Fibrosis. Dis Markers. 2016; 2016:4759040. PMC: 4886062. DOI: 10.1155/2016/4759040. View

13.

Yan S, Ramasamy R, Schmidt A . Soluble RAGE: therapy and biomarker in unraveling the RAGE axis in chronic disease and aging. Biochem Pharmacol. 2010; 79(10):1379-86. PMC: 2854502. DOI: 10.1016/j.bcp.2010.01.013. View

14.

Wu L, Ma L, Nicholson L, Black P . Advanced glycation end products and its receptor (RAGE) are increased in patients with COPD. Respir Med. 2010; 105(3):329-36. DOI: 10.1016/j.rmed.2010.11.001. View

15.

Ott C, Jacobs K, Haucke E, Navarrete Santos A, Grune T, Simm A . Role of advanced glycation end products in cellular signaling. Redox Biol. 2014; 2:411-29. PMC: 3949097. DOI: 10.1016/j.redox.2013.12.016. View

16.

Machahua C, Montes-Worboys A, Llatjos R, Escobar I, Dorca J, Molina-Molina M . Increased AGE-RAGE ratio in idiopathic pulmonary fibrosis. Respir Res. 2016; 17(1):144. PMC: 5097848. DOI: 10.1186/s12931-016-0460-2. View

17.

Vasakova M, Morell F, Walsh S, Leslie K, Raghu G . Hypersensitivity Pneumonitis: Perspectives in Diagnosis and Management. Am J Respir Crit Care Med. 2017; 196(6):680-689. DOI: 10.1164/rccm.201611-2201PP. View

18.

Izushi Y, Teshigawara K, Liu K, Wang D, Wake H, Takata K . Soluble form of the receptor for advanced glycation end-products attenuates inflammatory pathogenesis in a rat model of lipopolysaccharide-induced lung injury. J Pharmacol Sci. 2016; 130(4):226-34. DOI: 10.1016/j.jphs.2016.02.005. View

19.

Englert J, Hanford L, Kaminski N, Tobolewski J, Tan R, Fattman C . A role for the receptor for advanced glycation end products in idiopathic pulmonary fibrosis. Am J Pathol. 2008; 172(3):583-91. PMC: 2258251. DOI: 10.2353/ajpath.2008.070569. View

20.

Sukkar M, Ullah M, Gan W, Wark P, Chung K, Hughes J . RAGE: a new frontier in chronic airways disease. Br J Pharmacol. 2012; 167(6):1161-76. PMC: 3504985. DOI: 10.1111/j.1476-5381.2012.01984.x. View